سعر اوبيكاست 4مجم 21 اقراص مضغ 2022

Montelukast 4 mg chewable tablets, a leukotriene receptor antagonist for asthma and allergic rhinitis, Egyptian product (El-Obour).

• Prophylaxis and chronic treatment of asthma; acute prevention of exercise-induced bronchoconstriction (EIB); relief of seasonal/perennial allergic rhinitis symptoms when alternatives are inadequate. Not for acute asthma attacks.Population: Patients ≥2 years (asthma); ≥6 years (EIB); AR per label age bandsDailyMed (US National Library of Medicine)

• Common/labelled adverse reactions include upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhoea, otitis, influenza, rhinorrhea, sinusitis, and (chewable) thrush; neuropsychiatric events are highlighted in the boxed warning.International label, same formulation · DailyMed (US National Library of Medicine)

• Hypersensitivity to any component of montelukast sodium.International label, same formulation · DailyMed (US National Library of Medicine)

• Boxed warning: serious neuropsychiatric events have been reported; discuss benefits/risks, monitor for neuropsychiatric symptoms, and discontinue immediately if they occur. Do not use to treat an acute asthma attack; keep rescue medication available. Do not abruptly substitute for inhaled/oral corticosteroids. Patients with aspirin sensitivity should continue to avoid aspirin/NSAIDs. Systemic eosinophilia/Churg-Strauss-like vasculitis reported, sometimes with oral corticosteroid reduction.International label, same formulation · DailyMed (US National Library of Medicine)

• CYP3A4 / CYP2C8 / CYP2C9 inducers or inhibitors (e.g. phenobarbital, rifampin, gemfibrozil) — per label interaction sectionMontelukast is a CYP substrate; strong inducers may reduce exposure and gemfibrozil may increase exposure — follow the US label interaction guidance.DailyMed (US National Library of Medicine)

• Available data from decades of use have not established a drug-associated risk of major birth defects or miscarriage; use only if clearly needed per clinician judgment.International label, same formulation · DailyMed (US National Library of Medicine)
• Montelukast is present in human milk; available data do not suggest a significant risk of adverse effects on the breastfed infant; consider benefits of breastfeeding and of the drug to the mother.International label, same formulation · DailyMed (US National Library of Medicine)

• Montelukast: Orally active, selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor, blocking LTD4-mediated airway oedema, smooth-muscle contraction and inflammation (SINGULAIR US label).